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Anticoagulative strategies in reconstructive surgery –
clinical significance and applicability
Antikoagulatorische Strategien in der rekonstruktiven Chirurgie –
klinische Bedeutung und Anwendbarkeit
Abstract
Advanced strategies in reconstructive microsurgery and especially free
tissue transfer with advanced microvascular techniques have been
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routinely applied and continously refined for more than three decades
Andreas D.
Niederbichler
1
in day-to-day clinical work. Bearing in mind the success rates of more
than 95%, the value of these techniques in patient care and comfort
(one-step reconstruction of even the most complex tissue defects)
cannot be underestimated.
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However, anticoagulative protocols and practices are far from general
acceptance and – most importantly – lack the benchmark of evidence 1 Department of Plastic, Hand
and Reconstructive Surgery, basis while the reconstructive and microsurgical methods are mostly
standardized. Hanover Medical School,
Hanover, Germany Therefore, the aim of our work was to review the actual literature and
synoptically lay out the mechanisms of action of the plethora of antico-
agulative substances.
The pharmacologic prevention and the surgical intervention of
thrombembolic events represent an established and essential part of
microsurgery. The high success rates of microvascular free tissue
transfer as of today are due to treatment of patients in reconstructive
centers where proper patient selection, excellent microsurgical tech-
nique,tissuetransfertoadequaterecipientvessels,andearlyanastomot-
ic revision in case of thrombosis is provided. Whether the choice of
antithrombotic agents is a factor of success remains still unclear. Un-
doubtedly however the lack of microsurgical experience and bad tech-
nique can never be compensated by any regimen of antithrombotic
therapy. All the more, the development of consistent standards and al-
gorithms in reconstructive microsurgery is absolutely essential to opti-
mize clinical outcomes and increase multicentric and international
comparability of postoperative results and complications.
Keywords: anticoagulation, microsurgery, heparin-induced
thrombocytopenia (HiT), thrombosis
Zusammenfassung
DieFortschritteinderrekonstruktivenMikrochirurgieundinsbesondere
beimfreienGewebetransfermitsteterVerbesserungmikrochirurgischer
Techniken haben diese in den vergangenen 30 Jahren zu einem festen
Bestandteil in der täglichen Routine werden lassen.
Die mittlerweile erreichten Erfolgsraten von über 95% unterstreichen
den Wert der mikrochirurgischen Fortschritte für Patientenversorgung
und -komfort (Möglichkeit der primären Rekonstruktion komplexester
Verletzungen mit Hautweichteilverlust).
ObwohlrekonstruktiveundmikrochirurgischeTechnikenweitestgehend
standardisiert sind, fehlen bislang solche evidenzbasierten Standards
im Hinblick auf antikoagulatorische Regime.
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Review Article OPEN ACCESSZiel dieser Arbeit ist es daher, die Wirkmechanismen der für die Mikro-
chirurgierelevantenAntikoagulantienvordemHintergrundderaktuellen
Literatur zu diskutieren.
Die pharmakologische Prävention und chirurgische Intervention
thrombembolischer Ereignisse ist ein etablierter Bestandteil der Mikro-
chirurgie.DiemittlerweileerreichtenundhohenErfolgsratennachfreiem
mikrochirurgischen Gewebetransfer sind das Ergebnis der Behandlung
dieser Patienten in spezialisierten mikrochirurgischen Zentren mit ent-
sprechenderPatientenselektionimSinneeineradäquatenAuswahlder
Empfängergefäße und Möglichkeit der sofortigen Intervention im Falle
von thrombembolischen Komplikationen.
Inwieweit die Wahl der Antikoagulantien zum Erfolg des mikrochirurgi-
schen Gewebetransfers beiträgt, ist noch nicht hinreichend geklärt. Es
steht außer Zweifel, dass ein Mangel an mikrochirurgischer Expertise
und eine unzureichende Anastomosentechnik nicht durch antikoagula-
torische Regime kompensiert werden können.
Insofern ist die Etablierung antikoagulatorischer Standards und Algo-
rithmeninderrekonstruktivenMikrochirurgievordemHintergrundeiner
weiteren Optimierung und Vergleichbarkeit der klinischen Ergebnisse
der Zentren untereinander und auf internationaler Ebene unerlässlich.
Schlüsselwörter: Antikoagulation, Mikrochirurgie, Heparin-induzierte
Thrombozytopenie, Thrombose
Introduction
The quality of microsurgical anastomoses also depends
ontechnicalprerequisiteslikeadequateinstrumentsand
operation microscope, but mainly on the skill and experi-
enceofthemicrosurgeon.Thesuccessratesvarydepend-
ing on author, and professional experience in microsur-
gicalprocedures.Thenumberofself-conductedmicrovas-
cular free tissue transfers seems to be correlated with
anastomosis success rates.
Complicationsduetoinsufficientanastomosistechnique
are frequently deleterious and sometimes end up with
extremity loss for the patient.
Pharmacologicalthrombosisprophylaxis,butalso(micro-)
surgical interventions after thrombus formation are fre-
quently used techniques to prevent thrombogenic states
and rescue blood flow once a thrombus has formed and
obliterated the microvessel. Unfortunately, incoherent
guidelines and algorithms for thrombosis prophylaxis in
microsurgery are found in the literature, even though
basic science has clearly demonstrated the efficacy and
mechanisms of action of the various antithrombotic
agents in numerous experimental efforts.
Earlier on, Virchow has recognized and postulated the
pathophysiologic prerequisites endothelialdefect,hyper-
coagulabilityandstasis.Despitetheplethoraofavailable
antithrombotic substances, acetyl salicylic acid, heparin
(fractionated and unfractionated), hydroxyethyl starch
and dextrans are still the most frequently used agents.
While the guidelines and standards for inpatient and
outpatient antithrombotic prophylaxis in surgery have
beenclearlyoutlinedandagreedonbyamultidisciplinary
consensus conference, the german AWMF workgroup
(http://awmf.org/), such a protocol does not exist in
microsurgery yet.
Basics and principles of
antithrombotic therapy
Bearing Virchow’s trias in mind (endothelial wall, blood
flow, corpuscular and non-corpuscular composition of
the blood), the following therapeutic options can be
defined: Table 1.
Table 1: "Antithrombotic" measures
Successful microsurgical tissue transfer is based on an
adequate microsurgical technique by which correspond-
ingly high patency rates can be safely achieved. The
choice of the recipient vessel is centered around the es-
tablishment of sufficient microvascular blood flow, how-
ever, newer work has shown that the free flap itself is a
major determinant of blood inflow [1].
Beside these issues, the pathogenesis and localisation
of the tissue defect are also known predisposing factors
for microvessel (arterial and venous) thromboses espe-
ciallywhenlowerextremitydefectsandcomplextraumatic
tissuedefectswithconsecutivevesselocclusionorosteo-
myelitis need to be addressed [2].
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by the application of paverone – a temporal vasodilator
– to the anastomosis site. Postoperatively, prevention of
externalcompression(e.g.constrictivedressings,adverse
positioningetc.)tothemicroanstomosissiteorthemicro-
vessel course is absolutely necessary to avoid comprom-
ised microvascular blood flow.
Intraoperativeadministrationofheparin(“heparinflush”)
can be continued postoperatively by continuous i.v.,
subcutaneouslowmolecularheparinizationor–alternat-
ively – thrombocyte aggregation blockers (eg acetyl sali-
cylic acid 100 mg once daily p.o.).
Additionally an optimized fluid and volume management
and mechanoprophylaxis are proven perioperative treat-
mentoptionsinminimizingtheriskofvenousthromboem-
bolism.
Thrombosis and heparin-induced
thrombocytopenia (HiT)
Basedonourownexperiencewitheventsofflaplossdue
toheparin-associatedthrombocytopenia(HiT),addingon
to routine determination of partial thromboplastin time
(PTT)andinternationalnormalizedratio(INR),werecom-
mendtochecktheplateletcountduringthepostoperative
phase.
Lowered thrombocyte counts of more than 50% of the
baselinevaluewithinpostoperativedays5and10should
prompt the clinician to immediately withdraw heparin
administration and initiate the HiT diagnostic algorithm.
HiT type II (Heparin-induced
thrombocytopenia) – definition and
diagnostic process
HiT type II is a pharmacologically induced immune dys-
function syndrome and its clinical appearance is charac-
terized by thrombocytopenia and – paradoxically –
thrombotic events. Especially in reconstructive microsur-
gery thrombus formation can be associated with deleter-
ious sequelae like partial or complete flap loss. HiT type
IIisdiagnosedinapproximately5%ofallpatientstreated
with unfractionated heparin. Importantly, this rate is as
lowaslessthan1%ofallpatientsreceivinglowmolecular
weight heparin.
The diagnosis of HiT type II is based on three criteria:
1. Currenttreatmentwithheparinorsuspicionofongoing
heparin action in the case of prior heparin therapy
2. At least one clinical symptom is present (most fre-
quently thrombocytopenia)
3. Laboratorytesting(ELISA)revealsantibodyformation
against the heparin – platelet factor IV complex
(http://www.tigc.org/TheThrombosisInterestGroup
of Canada).
Thrombocytopenia is usually mild in patients diagnosed
with HiT type II. Platelet counts of lower than 30/nl is
rare,only5%ofthepatientshaveplateletcountsof15/nl
or lower. Bleeding complications are rarely encountered
inHiTIIpatientsandareusuallyassociatedwithconcom-
itant problems such as septicaemia or uremic thrombo-
cytopathy.
Paradoxically, patients with HiT type II display a higher
riskofdevelopingthromboticthanbleedingcomplications.
The cumulative risk for further enlargement of a pre-ex-
isting thrombosis or the development of new thrombotic
formations ranges from 30–50%. Clinically, thrombus
formation can also occur at later stages of the disease,
evenwhenheparinhasbeenstoppedandplateletcounts
begin to normalize.
Most thrombotic episodes are of venous origin, however,
arterial emboli may also occur. Typical thrombotic events
are deep vein thrombosis (DVT), pulmonary embolism
(PE), cerebral or myocardial infarction and emboli of the
arterial system of the lower extremities.
In HiT type II patients, autoantibodies are detectable in
the serum or plasma. Confirmation of a suspected HiT
type II diagnosis is done most frequently using ELISA
assays specific for autoantibodies against platelet factor
4 – heparin complexes (PF4-heparin-ELISA). Besides the
ELISA, two functional tests exist: The serotonin-liberation
assay,whichisdoneusing14C-serotonin-loadedplatelets
of healthy donors. If these are challenged with plasma of
a HiT II patient, the PF4-heparin-autoantibody complex
induces serotonin liberation.
Another functional test is the HIPA-test (heparin-induced
platelet activation), which is based on the mesurement
theactivationoffreshly-isolatedactivatedplatelets(from
healthydonors)bytheantigen-autoantibodycomplex[3],
[4].
In the case of a diagnosed HiT II heparin therapy should
be stopped immediately and nonheparin anticoagulants
should be administered in order to inhibit thrombin or
thrombin generation. Danaparoid, lepirudin and ar-
gatroban are approved anticoagulants for treatment of
HiT.Danaparoidisaglycosaminoglycuronanisolatedfrom
porcine intestinal mucosa and exerts its anticoagulant
effects predominantly by inhibiting factor Xa and to a
much lesser degree by inhibiting thrombin. Lepirudin is
arecombinanthirudin(r-hirudin)andadirectandirrevers-
ible inhibitor of thrombin. The primary elimination route
of lepirudin is renal, accounting for approximately 90%
of its systemic clearance [5]. The systemic clearance of
lepirudin is proportional to the glomerular filtration rate
andthereisarelevantcumulationofthisdruginpatients
with renal impairment [6]. Furthermore bleeding is the
most important and clinically relevant complication of
treatment with lepirudin when compared to oral or par-
enteral Xa inhibitors, with an incidence rate of 4%–19%
[7].
The activated partial thromboplastin time (aPTT) is the
current method of choice for monitoring treatment with
lepirudin. At plasma concentrations of lepirudin greater
than0.6mg/LthereisnolinearcorrelationbetweenaPTT
andlepirudinwhichmayresultinoverlookingtoxicdoses
and the danger of bleeding [8], [9], [10].
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the treatment of septic disorders during recent years ac-
cording to the fact, that thrombin is known to be a key
mediator of macrophage and granulocyte activation in
vitro [11].
Furthermore Thrombin has depressive effects on the cir-
culatory system reducing the functional capillary density
(FCD) via endothelial cell interaction and endothelial cell
damage [12].
ThereforeHoffmannetal.hypothesizedthathirudinwould
down-regulateleukocyte/endothelialcellinteractionand,
thereby, improve capillary perfusion [13]. They induced
severe endotoxemia in Syrian hamsters by intravenous
administration of endotoxin (lipopolysaccharide [LPS], E.
coli, 2 mg/kg) and could demonstrate a paradoxic effect
of hirudin on the leukocyte/endothelial cell interaction
andmicrocirculationbypronouncingleukocyteadherence
and deteriorating capillary perfusion [13]. On the other
handtheycoulddemonstrateaconsiderablemodulation
ofcoagulatoryparametersduringthefirst4hofendotox-
emia. Hirudin prevented the increase in thromboplastin
time and induced an improvement of antithrombin
activity and a tendency towards higher protein C activity,
as well as shorter partial thromboplastin time. Further-
more hirudin did not induce a change in platelet count
excluding a distinct effect on platelet-endothelial cell
interaction.
Inconclusion,theirexperimentsdonotindicatearelevant
protective effect of recombinant hirudin on endotoxin-in-
duced microcirculatory disorders [13].
Danaparoid in a high dose regimen is equivalent to
lepirudininthetreatmentofHiTwithorwithoutthrombos-
is. Reduction in the incidence of new thromboembolic
complications and limb amputation is comparable with
lepirudin [14].
Argatroban, a direct inhibitor of thrombin and is cleared
by the liver and, therefore, can be used safely in patients
withrenalinsufficiency.Argatrobanalsohastheshortest
half-life among all alternative anticoagulants and can be
discontinuedquicklyifinvasiveproceduresarenecessary
or if bleeding is encountered [15].
Differential diagnosis of HiT type II
Thrombocytopenias of other origin, e.g. HiT type I, have
to be differentiated from HiT type II. The clinical course
of HiT type I is characterized by a steep decrease of the
platelet count within the early phase of heparin therapy
(usually the first 4 days after initiation), which does usu-
ally not worsen under continous heparin therapy and re-
solves despite the ongoing administration of heparin.
Platelet counts usually do not reach values lower than
50%ofthebaselineandlessthan100/nl.HiTtypeIdoes
not induce a thrombophilic state and does not require
heparin withdrawal or change of the antithrombotic regi-
men. Besides HiT type I, the differential diagnostic pro-
cess should prompt the clinician to take disseminated
intravascular coagulopathy (DIC) and thrombotic-throm-
bocytopenic purpura (TTP) as well as other non-specific
syndromes resulting in platelet activation into account.
Here, the mechanism is characterized by the formation
of immune complexes. Also, pharmacologically induced
immunogenicthrombocytopeniasor–rarely–alloimmun-
ethrombocytopenias (e.g. posttransfusion purpura,
neonatal alloimmunethrombocytopenia) have to be kept
in mind during the differential diagnosis process [16].
It is of utmost importance to determine the preoperative
baseline platelet count.
Perioperative antithrombotic
measures – general and specific
aspects
As outlined in Table 2, pharmacological treatment and
operative measures add on to each other and standard-
ized algorithms have been consented by the respective
societies.
Table 2: Antithrombotic measures in the perioperative setting
Unfortunately, generally accepted standards regarding
the anticoagulative protocols in microsurgical free flap
transfer do not exist.
Startingtoaddressthelackofstandardizationforantico-
agulativeprotocolsweintroducedanalgorithmregarding
prophylaxis of venous thrombembolism for the field of
plastic surgery. Indications for the pharmacological pro-
phylaxis of thromboembolic events are here oriented on
thespecificriskcategoriesforsurgicalinterventionswith
regard to the “exposing” (associated with the clinical
setting) and “predisposing” (associated with the patient)
risk factors. Furthermore, the recommendations for the
fieldofplasticandreconstructivesurgeryaresubdivided
into the various regions of the body [17].
An-up-to-date survey, which was done at the 29
th annual
meeting of the german-speaking society of microsurgery
revealed the following (Table 3, rate of return 10%).
To undermine these heterogeneous data we performed
a further and comprehensive survey among german
speaking microsurgeons whose results are going to be
published in the near future.
Table 3 shows that acetyl salicylic acid (100–500 mg/d)
and unfractionated or low-molecular weight heparin are
used. Dextrans have disappeared from routine clinical
use, however, hydroxyl ethyl starch is used during the
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postoperative phase. Intraoperatively, flushing of the
anastomosis site is done with either heparin or – in the
case of an existing thrombus – rt-PA (Urokinase, lysis).
Lookingattheincreasedbleedingriskandotheradverse
reactions, rt-PA should be used cautiously. A general re-
commendation cannot be given at this point, because
randomized,prospectivestudieshavenotbeendoneyet.
Evenintraoperativeheparinflushingisnotroutinelydone
in all microsurgical units.
In2007,Xipoleasetal.presentedtheresultsofanemail-
and questionnaire based survey among members of the
American Society of Plastic Surgeons [18]. In summary,
4,383 members were asked to complete the survey. Fi-
nally, the data was analyzed upon a feedback rate of 3%,
the number of performed procedures ranged from 5 to
84 cases per year. Nevertheless, the success rates were
not evenly distributed over 90%, but did reach maximum
success rates of 92–100%. 84% of the surgeons did at
least use a form of anticoagulation during or after micro-
surgical flap transfer. 48% of the surgeons applied a
combination therapy, 44.9% started the anticoagulative
treatment intraoperatively and maintained it postoperat-
ively. 16.3% did not use any form of anticoagulation at
any time during the treatment [18]. A potential reason
for the non-standardized anticoagulative regimens from
aeuropeanpointofviewmaybethedifferenceinpatient
management with lack of preoperative hospitalization of
the patients in the United States. In contrast, a wide
variation concerning intraoperative anticoagulation
measures was found when the respective pathogenesis
oftissuedefectswastakenintoconsideration.Potentially,
differences in the therapeutic approaches due to defect
pathogenesis may count for these variations, so that
standardized protocols cannot be established.
Apparently, many surgeons base their anticoagulative
regimen upon their personal professional experiences
and case observations. Indeed, it was interesting to note
that personal standards have been changed primarily
after complications were encountered, which can be de-
duced from a study conducted by Khouri and colleagues
[2]. Intraoperative thrombus formation was associated
with the use of myocutaneous flaps and vein grafts. The
flap loss rate was reported at 4.1 %, the intra- and post-
operativethrombosisraterangedbetween8.3and9.9%.
Statistically, there was no association between the used
anticoagulativestrategyandanastomosisinsufficiencies.
However, an increased risk of complications was noted
when chronic wounds were treated or when interposition
vein grafts were used. A lower risk ratio was found when
rectusabdominismuscleflapsandpostoperativesubcuta-
neous low-molecular-weight heparin therapy had been
applied [2].
In our clinic we administer low molecular weight heparin
(2500–5000IEbodyweightadapted)startingtheevening
before surgery. Intraoperatively we flush the flap and re-
cipient vessels with unfractioned heparin (50 IE/ml) and
administer1000IEunfractionedheparinaftercompletion
of the microanastomosis respectively before clamp re-
lease. In the case of complicated anastomosis (e.g. ath-
erosclerosis,AV-loop)weperformsystemicheparinization
(15000 IE/24 hours resp. PTT 50–60 sec.) for 10 days.
Papaverineisonlyappliedinvasospasmsattheanastom-
osissite.Inthepostoperativesettingourregimenconsists
of aspirin 100 mg and low molecular weight heparin
(2500–5000 IE body weight adapted) once a day for 7
days.
Additionally we start a combined dangling/wrapping pro-
cedure respectively ischemic conditioning at day 3 after
surgery consisting of a combined cotton and elastic
wrapping of the flap followed by dangling the lower ex-
tremity with the patient sitting in an upright position at
the edge of the bed and the knee joint flexed at an angle
of 90°. The heel is not supported.
Wrapping and dangling the flap starts with a duration of
5 minutes three times a day and increases daily by
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Protection of microanastomoses and microcirculation by antithrombotic substances
doubling the duration over a period of 4 days reaching
60 minutes at day 5.
This combined dangling/wrapping procedure in the
postoperativecourseafterlowerextremityreconstruction
counteracts adverse events of free-flap transfer (i.e.
venous congestion due to increased capillary pressure
and fluid leaking into the interstitium; decreased perfu-
sion due to division of sympathetic nerves and inflow
vessels) by supporting venous and lymphatic return, re-
ducing edema and increasing blood flow to the flap by
inosculation and neovascularization by ischemic condi-
tioning [19], [20].
Acetylsalicylicacidisattributedauniversalefficacyinthe
prophylaxisofarterial,venousandautograftanastomoses
as well as a beneficial microcirculatory effects. These
universal properties could have even been shown for
heparin (Table 4).
Nevertheless, a rationale for its clinical application can
beformulated,especiallyforthepathophysiologicconcept
ofischemia-reperfusioninjury:ThromboxaneA2mediates
vasoconstriction, O2 radicals damage membrane lipids,
receptors and other important biomolecules. An array of
specific anti-inflammatory cytokines, leukotrienes and
interleukins finally induces an endothelial injury which in
turn completes the reperfusion injury in concert with ac-
tivated leucocytes. Bearing these mechanisms in mind,
antithromboticsubstancesseemtobeclinicallyindispens-
able and their mechanisms of action are divert:
Acetylsalicylic acid is a platelet aggregation inhibitor. Via
irreversible blocking of cyclooxygenases the synthesis of
thromboxane A2 is effectively intercepted. Treatment
doses of 30–300 mg per day are known to effectively
inhibit thromboxane synthesis. In higher doses, additive
inhibition of the prostacyclin synthesis has been shown.
Peter et al. have demonstrated earlier on in an isolated
muscle system that acetylsalicylic acid can also induce
an increase in the functional density of microcapillary
networks[21].However,themaineffectsofacetylsalicylic
acid are centered around the local endothelial effects
anditsactiononplateletfunction.Effectorsoftheclotting
cascade are not influenced by acetylsalicylic acid. Here,
heparin is an efficient antithrombin III (AT III) agonist and
is an inhibitor of the factors IIa, IXa, Xa, XIa and XIIa.
Moreover, heparin indirectly influences platelet aggrega-
tion via inhibition of endothelial prostacyclin.
In summary, acetylsalicylic acid inhibits thrombus forma-
tion by the inhibition of platelet aggregation while the
mechanism of action of heparin inhibits thrombin (indir-
ectly) and the clotting factor Xa thereby preventing
thrombusformationlocally(anastomosissite).Therefore,
sole inhibition of platelet aggregation seems to be insuf-
ficient in microsurgery because thrombus formation can
still occur via the alternative, plasmatic pathway of the
clotting cascade which can be modulated by heparin ap-
plication.
Greenbergandcoworkershaverecentlyshowninarabbit
model that intraarterial perfusion with heparin for 72
hoursaftersurgeryleadstoanoverallhigheranastomosis
patency rate [22].
Overall, systemic application seems to be less effective
than local heparin application. It has been shown that
lower molecular weight heparin is more effective than
intravenous heparin in free flap transfer [23], [24], [25].
Studies in coronary surgery have demonstrated that
heparin induced a significantly higher rate of postopera-
tive vessel patency (30%). Also, analyses of the outcome
after coronary thrombolysis therapy have shown that
heparinismoreefficientinpost-lysisanticoagulationthan
acetylsalicylic acid [26]. However, these results are in
contrast to a prospective multicenter analysis which was
done in 1998 by Khouri and colleagues [2]. The compar-
isonofanticoagulatorystrategiesofexperiencedmicrosur-
geons and the respective influence on the complication
rates after microvascular tissue transfer did not reveal
any preventive effects on thrombus formation of intraop-
erativelyadministeredheparin.Postoperativeprophylaxis
with low-molecular weight heparins which were applied
subcutaneously lowered the risk of postoperative throm-
bosis [2].
Microsurgicalinterventionsandflap
failure
Anticipationandpreventionarekeyfactorsforsuccessful
flap transfer procedures, and they are built on surgical
tactics on the one hand and the preoperatively started
pharmacoprophylaxis on the other hand.
Surgical planning consists of adequate clinical and tech-
nical diagnostic procedures to select the best suitable
flap and the safest recipient vessels. Defect size, localiz-
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defect site, vessel disease of any kind etc are central
elements which need to be considered preoperatively at
the stage of surgical planning.
In the case of thrombotic microvessel occlusion, the
anastomosis itself can be revised and redone, a new re-
cipientsitecanbechosenoradditionalvenousanastom-
oses can be performed to ensure an optimal in- and out-
flow balance. Pharmacologically, multiple thrombolytic
protocols which can also be performed intraoperatively,
are discussed in literature [27], [28], [29], [30].
There is no doubt that sole use of pharmacologic antith-
rombotic therapy cannot increase the success rate of
flaps. The surgical revision of the anastomosis site is still
essential and a key rescue procedure. A study by Smit
and coworkers recently demonstrated that only early
surgicalinterventionssuchasresuturingtheanastomosis,
thrombectomyandplacementofinterpositionveingrafts
etc.canreduceflapfailurerates.Themajorityofanastom-
osis patency complications were encountered within the
first 24 hours after surgery and decreased later on in
frequency. Operative revisions displayed a success rate
of approximately 80% on day 1 after surgery, however,
this rate decreases continuously with time and reach a
baseline rate of lower than 5% by days 6 and 7 after the
initial procedure [31]. Another important surgical inter-
vention in the case of thrombotic complications is intra-
operative vasodilatation: Evans and colleagues have
shown in 1997 that local and systemic application of
lidocaine rather induce vasospasms of the anastomosis
vessels, in contrast, prostaglandin E1 and papaverine
hydrochloride induce vasodilatation and a consecutive
increase in regional blood flow [32]. Therefore, lidocaine
applicationseemstobeobsoleteinmodernmicrosurgery.
Whether intraluminal irrigation using antithrombotic
substances can be generally recommended for clinical
usecannotbepredictedatthispointoftime.Afirststudy
which was published by Khouri et al. in 2001 at least
demonstrated that low-dose application of TPFI in com-
parison to heparin does not only have acceptable antith-
romboticprophylacticpropertiesbutwasalsoassociated
with lower complication rates, especially hematoma
formation [33].
Of course, the local factors of the recipient area are still
considered key factors for surgical success and the re-
sulting flap perfusion. Free flap transfers to the lower
limb after complex trauma to the zone of injury are asso-
ciated with high complication rates, therefore, subtle
surgicalplanningandmeticuloustechniqueareessential
factors for success. It is very interesting to observe that
not the recipient vessel, but the blood intake capacity of
the flap determines the flow rates. In this context,
Lorenzetti and Ascarseria demonstrated that in free
rectus abdominis muscle flaps the flow rate in the flap
afteranastomosiswaswidelyidenticaltothecorrespond-
ing flow rate in the inferior epigastric artery as the donor
vessel. In contrast, the flow rates determined preoperat-
ivelyinthethoracodorsalarteryasthedonorvesselwere
significantly different to the flow measured in the rectus
abdominismuscleflap.Conclusively,theflowratesseem
to be regulated by the demand in the graft itself and its
uptake capacity [1].
Influence of chemotherapy on
microanastomosisandflapsurvival
Intraarterial chemotherapy with various substances is a
modern and efficient approach to increase local doses
ofthecytostaticagentandreducesystemictoxicityatthe
same time. Also, isolated hyperthermic limb perfusion
(ILP)isusedincertaintypesofsofttissuetumors.Astudy
by Sadrian and coworkers has revealed no flap loss due
to thrombosis formation in a cohort of tumor patients
that underwent either hyperthermic limb perfusion or in-
traarterialchemotherapyafterfreeflaptransfer.Thestudy
included patients from two cancer centers [34]. In con-
nectionwiththeresultsofthisstudy,aninterestingnovel
approach to maximize patient safety and flap success is
the creation of an arteriovenous loop (AV-loop) and sub-
sequentflaptransfertothetransectedloopvessel(arter-
ial and venous side). However, own studies could not
verifyclinicaladvantageswhensingle-stage(“fixandflap”
approach) or two-step procedures were used to perform
the flap transfer [35]. Nevertheless, it must be emphas-
izedthatinanycaseoffreetissuetransfertheprofession-
al experience of the surgeon, surgical skills and meticu-
lous assessment of the anastomosis site are pivotal
factors determining flap success and outcome.
Case report
We report about a 56-years-old man who suffered from
a lawn cutter injury and had an open tarsal and ankle
joint fracture that was initially treated by our trauma sur-
geons. The patient was transferred to our plastic surgery
department with an exposed osteosynthesis plate at the
ankle joint level and a soft tissue defect measuring
10x20 cm due to tissue break down. We perfomed an
free fasciocutanous anterior lateral thigh perforator flap
for defect coverage. After microsurgical end-to-side ana-
stomosis of the perforator flap vessels to the tibial pos-
terior artery and a concommitant vein additional skin
grafts have been performed. Due to uncomplicated mi-
crosurgery (Figure 1) this patient received the standard
anticoagulative protocol with oral ASS 100 mg and
5000IElowmolecularweightheparins.c.onadailybasis
inthepostoperativesetting.Atdayoneafterflaptransfer
the patient was taken back to the operating room to
evacuate a haematoma. At day two the flap presented a
significant change towards livid colouration of the skin
islandindicatingvenouscongestionrespectivelyflapvein
thrombosis and revision was necessary (Figure 2). After
revisionofthevenousanastomosistheflapwassalvaged
by thrombectomy and interposition of a vein graft
(Figure 3). In this case the anticoagulative regimen was
not changed towards unfractioned heparin due to the
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Figure 2: Livid colouration of the skin island indicating venous congestion respectively flap vein thrombosis due to hematoma
formation
8/12 GMS German Medical Science 2012, Vol. 10, ISSN 1612-3174
Jokuszies et al.: Anticoagulative strategies in reconstructive surgery ...Figure 3: Free flap salvage after thrombectomy and interposition of a vein graft
fact, that flap vein thrombosis occurred because of
hematoma formation followed by external compression
of the anastomosis and not because of disturbance of
the coagulative state. Therefore the standard anticoagu-
lative protocol with oral ASS 100 mg and s.c. low weight
heparine 5000 IE on a daily basis was maintained.
Discussion
Thromboses after microvascular tissue transfer have
technical and hematologic reasons. While operative
standards have been clinically defined, internationally
accepted standards in pharmacologic antithrombotic
prophylaxisinreconstructivemicrosurgeryhavenotbeen
clearly outlined yet. However, there is great consent that
surgical skills and experience of the reconstructive mi-
crosurgeonarepivotalfactorsforflapsuccessandfavour-
able outcomes.
International studies and our own data (pulse survey)
have revealed that heparin is the most frequently used
substanceforantithromboticprophylaxisinreconstructive
microsurgery.Heparinisusedpre-,intra-andpostoperat-
ively.Whenusedasasingleantithromboticagent,heparin
seems to be more effective compared to aspirin. Never-
theless, one has to keep in mind that the use of unfrac-
tioned heparin may induce grave complications such as
HiT type II and therefore its indication and dosage has to
be reevaluated on a day-to-day and clinical situation-ori-
ented basis. In the case of suspected HiT type II, it is re-
commendedtostopheparinimmediately,switchtoother
antithromboticagents(e.g.lepirudinetc.)andinitiateHiT
screening.
Overall, microvascular tissue transfer procedures have
a high success rate and can be confidently applied even
in adverse clinical situations. However, establishment of
clinical algorithms and standards for antithrombotic pro-
phylaxis in reconstructive microsurgery are of utmost
importance. In our view, it is unlikely that a simple al-
gorithm in microsurgery will be defining antithrombotic
prophylaxis in general, rather, consideration and integra-
tion of the various pathogenetic aspects, comorbidities
and risk factors will have to be done to define individual
“standardoperatingprocedures”foragivenmicrosurgical
9/12 GMS German Medical Science 2012, Vol. 10, ISSN 1612-3174
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toward this goal and we are confident that applicable
solutions can be found within reasonable amounts of
time.
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